[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR102015031283A2 - Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento - Google Patents

Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento Download PDF

Info

Publication number
BR102015031283A2
BR102015031283A2 BR102015031283A BR102015031283A BR102015031283A2 BR 102015031283 A2 BR102015031283 A2 BR 102015031283A2 BR 102015031283 A BR102015031283 A BR 102015031283A BR 102015031283 A BR102015031283 A BR 102015031283A BR 102015031283 A2 BR102015031283 A2 BR 102015031283A2
Authority
BR
Brazil
Prior art keywords
amylin
bioconjugate
insulin
aggregating
composition
Prior art date
Application number
BR102015031283A
Other languages
English (en)
Portuguese (pt)
Inventor
Melo Vieira Gonçalves Ferreira Bruno
Mauricio Trambaioli Da Rocha E Lima Luis
Henrique Guerreiro Rosado Luiz
Fernandes De Avila Netto Guterres Mariana
Original Assignee
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rio De Janeiro filed Critical Univ Rio De Janeiro
Priority to BR102015031283A priority Critical patent/BR102015031283A2/pt
Priority to JP2018549371A priority patent/JP2019501963A/ja
Priority to CA3008182A priority patent/CA3008182A1/en
Priority to MX2018007236A priority patent/MX2018007236A/es
Priority to KR1020187020206A priority patent/KR20180093059A/ko
Priority to CN201680073149.XA priority patent/CN108431031A/zh
Priority to AU2016371260A priority patent/AU2016371260A1/en
Priority to PCT/BR2016/050330 priority patent/WO2017100896A1/en
Priority to BR112018011903A priority patent/BR112018011903A2/pt
Publication of BR102015031283A2 publication Critical patent/BR102015031283A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
BR102015031283A 2015-12-14 2015-12-14 Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento BR102015031283A2 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR102015031283A BR102015031283A2 (pt) 2015-12-14 2015-12-14 Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
JP2018549371A JP2019501963A (ja) 2015-12-14 2016-12-14 アミリンおよびアミリンミメティック化合物の非凝集性バイオコンジュゲート、それを含む組成物、ならびにその製造および使用
CA3008182A CA3008182A1 (en) 2015-12-14 2016-12-14 Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof
MX2018007236A MX2018007236A (es) 2015-12-14 2016-12-14 Bioconjugados no aglomerantes de amilina y compuestos mimeticos de amilina, composiciones que comprenden los mismos, y fabricacion y uso de los mismos.
KR1020187020206A KR20180093059A (ko) 2015-12-14 2016-12-14 아밀린 및 아밀린-모방 화합물의 비-응집성 바이오접합체, 이를 포함하는 조성물 및 이의 제조 방법과 용도
CN201680073149.XA CN108431031A (zh) 2015-12-14 2016-12-14 胰淀素和胰淀素拟似化合物的非聚集生物缀合物、包含其的组合物及其制备和用途
AU2016371260A AU2016371260A1 (en) 2015-12-14 2016-12-14 Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof
PCT/BR2016/050330 WO2017100896A1 (en) 2015-12-14 2016-12-14 Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof
BR112018011903A BR112018011903A2 (pt) 2015-12-14 2016-12-14 bioconjugado não aglomerante de amilina humana ou análogo de amilina, composição, métodos para preparar uma composição, para tratar uma doença ou condição causada por uma falta de amilina ou deposição ou acúmulo de amiloide e para estabilizar um composto amilinomimético, e, medicamento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102015031283A BR102015031283A2 (pt) 2015-12-14 2015-12-14 Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento

Publications (1)

Publication Number Publication Date
BR102015031283A2 true BR102015031283A2 (pt) 2018-09-18

Family

ID=59055492

Family Applications (2)

Application Number Title Priority Date Filing Date
BR102015031283A BR102015031283A2 (pt) 2015-12-14 2015-12-14 Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
BR112018011903A BR112018011903A2 (pt) 2015-12-14 2016-12-14 bioconjugado não aglomerante de amilina humana ou análogo de amilina, composição, métodos para preparar uma composição, para tratar uma doença ou condição causada por uma falta de amilina ou deposição ou acúmulo de amiloide e para estabilizar um composto amilinomimético, e, medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018011903A BR112018011903A2 (pt) 2015-12-14 2016-12-14 bioconjugado não aglomerante de amilina humana ou análogo de amilina, composição, métodos para preparar uma composição, para tratar uma doença ou condição causada por uma falta de amilina ou deposição ou acúmulo de amiloide e para estabilizar um composto amilinomimético, e, medicamento

Country Status (8)

Country Link
JP (1) JP2019501963A (es)
KR (1) KR20180093059A (es)
CN (1) CN108431031A (es)
AU (1) AU2016371260A1 (es)
BR (2) BR102015031283A2 (es)
CA (1) CA3008182A1 (es)
MX (1) MX2018007236A (es)
WO (1) WO2017100896A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005320351B2 (en) * 2004-02-11 2010-06-03 Amylin Pharmaceuticals, Llc Amylin family peptides and methods for making and using them
US8486890B2 (en) * 2006-03-15 2013-07-16 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
AU2012208349A1 (en) * 2011-01-20 2013-07-18 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.

Also Published As

Publication number Publication date
CA3008182A1 (en) 2017-06-22
CN108431031A (zh) 2018-08-21
BR112018011903A2 (pt) 2018-11-27
MX2018007236A (es) 2019-03-14
JP2019501963A (ja) 2019-01-24
AU2016371260A1 (en) 2018-06-21
KR20180093059A (ko) 2018-08-20
WO2017100896A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
US20240342249A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
JP7064103B2 (ja) アミリン類似体
ES2328579T3 (es) Derivados de insulina de larga duracion y procedimientos asociados.
TW201904607A (zh) 用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
CA2979950A1 (en) Amylin analogues
BR112021005858A2 (pt) formulações de análogos de peptídeo semelhante a glucagon 2 (glp-2)
EA028951B1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
BR102015031283A2 (pt) Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
US20210401945A1 (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
US20160184401A1 (en) Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
EP3856767A1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
US11590205B2 (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP3394090A1 (en) Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof
WO2023001186A1 (zh) 多肽缀合物在制备治疗糖代谢相关疾病的药物中的应用
RU2819934C1 (ru) Жидкие составы аналогов глюкагона
US11191806B2 (en) Polymyxin-based pharmaceutical composition for treating infectious diseases
US20240350590A1 (en) Composition for orally administered formulation containing glp-1 analogue
US20240148678A1 (en) Sustained release injectable therapeutic formulations using aprotic polar solvents

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired